Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

10.09.23	AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC (PR Newswire)
07.09.23	AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
01.09.23	Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4 (RTTNews)
01.09.23	AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION (PR Newswire)
01.09.23	AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
29.08.23	Initial Medications Chosen By HHS For Medicare Drug Price Negotiations (RTTNews)
26.08.23	Amgen : Olpasiran Phase 2 Data Shows Continued Reduction Of Lp(a) Nearly A Year After Last Dose (RTTNews)
26.08.23	AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023 (PR Newswire)
21.08.23	AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING (PR Newswire)
03.08.23	Amgen Inc. Q2 Profit Increases, beats estimates (RTTNews)
01.08.23	AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND (PR Newswire)
31.07.23	AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS (PR Newswire)
21.06.23	Amgen: FDA Grants Full Approval For BLINCYTO - Quick Facts (RTTNews)
21.06.23	FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (PR Newswire)
09.06.23	AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE (PR Newswire)
04.06.23	AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023 (PR Newswire)
01.06.23	AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023 (PR Newswire)
31.05.23	AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023 (PR Newswire)
26.05.23	AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT (PR Newswire)
22.05.23	IDEAYA: FDA Approves To Proceed With Evaluation Of IDE397 In Combination With AMG 193 (RTTNews)
19.05.23	U.S. Supreme Court Rules Against Amgen In Cholesterol Drug Patent Dispute With Sanofi (RTTNews)
17.05.23	FTC Sues To Block Amgen's $27.8 Bln Acquisition Of Horizon Therapeutics (RTTNews)
16.05.23	AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS (PR Newswire)
16.05.23	FTC To Sue To Block Amgen's Acquisition Of Horizon Therapeutics : Reports (RTTNews)
09.05.23	AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE (PR Newswire)
09.05.23	AMGN FINAL DEADLINE MAY 12: ROSEN, A TOP RANKED LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AMGN (PR Newswire)
08.05.23	Amgen: Prolia Shows Greater Fracture Risk Reduction Than With Alendronate In Real-world Study (RTTNews)
08.05.23	NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE (PR Newswire)
29.04.23	ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN (PR Newswire)
27.04.23	Amgen Inc. Q1 Profit Increases, beats estimates (RTTNews)
27.04.23	AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS (PR Newswire)
23.04.23	ROSEN, A RESPECTED AND LEADING FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN (PR Newswire)
21.04.23	AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS (PR Newswire)
19.04.23	AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST) (PR Newswire)
15.04.23	ROSEN, A TOP RANKED FIRM, Encourages Amgen Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN (PR Newswire)
07.04.23	ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN (PR Newswire)
31.03.23	ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN (PR Newswire)
24.03.23	ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN (PR Newswire)
16.03.23	AMGN ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amgen Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMGN (PR Newswire)
09.03.23	AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE (PR Newswire)
07.03.23	AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND (PR Newswire)
03.03.23	AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE (PR Newswire)
01.03.23	AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC (PR Newswire)
22.02.23	AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS (PR Newswire)
09.02.23	AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE (PR Newswire)
02.02.23	AstraZeneca, Amgen's Tezspire Pre-filled Pen Receives FDA Approval In US For Asthma (RTTNews)
02.02.23	TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN (PR Newswire)
01.02.23	AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST (PR Newswire)
31.01.23	Amgen Inc. Bottom Line Declines In Q4 (RTTNews)
31.01.23	AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

26.11.24		Dow Jones aktuell: Dow Jones zum Handelsende in Grün
26.11.24		Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100
26.11.24		Börse New York: Dow Jones wenig verändert
26.11.24		Starker Wochentag in New York: NASDAQ 100-Anleger greifen am Nachmittag zu
26.11.24		Starker Wochentag in New York: S&P 500 präsentiert sich fester
26.11.24		Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester
26.11.24		Optimismus in New York: S&P 500 legt am Dienstagmittag zu
26.11.24		Pluszeichen in New York: NASDAQ Composite mittags in Grün

26.11.24

Dow Jones aktuell: Dow Jones zum Handelsende in Grün

26.11.24

Zuversicht in New York: Zum Handelsende Gewinne im NASDAQ 100

26.11.24

Börse New York: Dow Jones wenig verändert

26.11.24

Starker Wochentag in New York: NASDAQ 100-Anleger greifen am Nachmittag zu

26.11.24

Starker Wochentag in New York: S&P 500 präsentiert sich fester

26.11.24

Starker Wochentag in New York: NASDAQ Composite präsentiert sich nachmittags fester